Drugs / rQNestin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03152318 | Jul 2017 → Jan 2027 expected | anaplastic oligodendroglioma, astrocytoma (excluding glioblastoma), brain cancer, ependymoma +4 | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rQNestin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03152318 ↗ |
| Route | Other | “It is administered via intratumoral injection during biopsy surgery.” NCT03152318 ↗ |